Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer

[1]  H. Gelderblom,et al.  Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. , 2020, Future oncology.

[2]  Gennady Korotkevich,et al.  Fast gene set enrichment analysis , 2019, bioRxiv.

[3]  D. Stolz,et al.  Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ. , 2019, Immunity.

[4]  G. Shapiro,et al.  PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. , 2019, Cancer discovery.

[5]  Wei Li,et al.  OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  L. Coussens,et al.  Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors , 2019, Therapeutic advances in medical oncology.

[7]  Ramin Rad,et al.  Web-Based Search Tool for Visualizing Instrument Performance Using the Triple Knockout (TKO) Proteome Standard. , 2018, Journal of proteome research.

[8]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[9]  H. Gong,et al.  Inhibition of Poly(ADP-Ribose) Polymerase Increased Lipid Accumulation Through SREBP1 Modulation , 2018, Cellular Physiology and Biochemistry.

[10]  John N. Hutchinson,et al.  IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization , 2018, Nature Cell Biology.

[11]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[12]  J. Jonkers,et al.  Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors , 2018, bioRxiv.

[13]  E. Coccia,et al.  Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth , 2018, Proceedings of the National Academy of Sciences.

[14]  M. Ceppi,et al.  Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis , 2018, ESMO Open.

[15]  Sandro Santagata,et al.  Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes , 2018, eLife.

[16]  Jennifer L. Guerriero.  Macrophages: The Road Less Traveled, Changing Anticancer Therapy. , 2018, Trends in molecular medicine.

[17]  S. Snyder,et al.  Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases , 2018, British journal of pharmacology.

[18]  Astrid Gall,et al.  Ensembl 2018 , 2017, Nucleic Acids Res..

[19]  A. Ashworth,et al.  Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance , 2017, bioRxiv.

[20]  T. Sørlie,et al.  Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. , 2017, Cancer discovery.

[21]  Yi Zhang,et al.  Tumor-associated macrophages, potential targets for cancer treatment , 2017, Biomarker Research.

[22]  S. Takenoshita,et al.  Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. , 2017, Oncology letters.

[23]  Arnab Ray Chaudhuri,et al.  The multifaceted roles of PARP1 in DNA repair and chromatin remodelling , 2017, Nature Reviews Molecular Cell Biology.

[24]  C. Perou,et al.  Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer , 2017, Science Translational Medicine.

[25]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[26]  Xiao-dong Zhu,et al.  Colony-stimulating factor-1-induced AIF1 expression in tumor-associated macrophages enhances the progression of hepatocellular carcinoma , 2017, Oncoimmunology.

[27]  A. Letai,et al.  Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages , 2017, Nature.

[28]  M. Brand,et al.  Quantifying intracellular rates of glycolytic and oxidative ATP production and consumption using extracellular flux measurements , 2017, The Journal of Biological Chemistry.

[29]  J. Yélamos,et al.  PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas , 2017, Scientific Reports.

[30]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[31]  Patrick Danaher,et al.  Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.

[32]  Lior Pachter,et al.  Differential analysis of RNA-seq incorporating quantification uncertainty , 2016, Nature Methods.

[33]  P. Sorger,et al.  Cyclic Immunofluorescence (CycIF), A Highly Multiplexed Method for Single‐cell Imaging , 2016, Current protocols in chemical biology.

[34]  Steven P Gygi,et al.  Quantitative mass spectrometry-based multiplexing compares the abundance of 5000 S. cerevisiae proteins across 10 carbon sources. , 2016, Journal of proteomics.

[35]  John Kidd,et al.  Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Pittet,et al.  The role of myeloid cells in cancer therapies , 2016, Nature Reviews Cancer.

[37]  Alexey Sergushichev,et al.  An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation , 2016 .

[38]  Eric C. Holland,et al.  The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas , 2016, Science.

[39]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[40]  K. Moore,et al.  Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages* , 2016, The Journal of Biological Chemistry.

[41]  Daniel J. Gaffney,et al.  A survey of best practices for RNA-seq data analysis , 2016, Genome Biology.

[42]  Phillip G. Popovich,et al.  Novel Markers to Delineate Murine M1 and M2 Macrophages , 2015, PloS one.

[43]  Peter K. Sorger,et al.  Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method , 2015, Nature Communications.

[44]  L. Molinero,et al.  Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) , 2015 .

[45]  J. Blay,et al.  CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. , 2015, The Lancet. Oncology.

[46]  P. Chakravarty,et al.  GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. , 2015, Immunity.

[47]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  C. Ries,et al.  Targeting tumor-associated macrophages in cancer therapy and understanding their complexity , 2014, Oncoimmunology.

[49]  Zhongyu Yuan,et al.  High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis , 2014, OncoTargets and therapy.

[50]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[51]  Edward L. Huttlin,et al.  MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes , 2014, Analytical chemistry.

[52]  Pornpimol Charoentong,et al.  High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer , 2014, BMC Cancer.

[53]  B. Kempkes,et al.  Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages , 2013, PloS one.

[54]  G. Shapiro,et al.  Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance , 2013, Proceedings of the National Academy of Sciences.

[55]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[56]  Carl Grunfeld,et al.  Mechanisms of triglyceride accumulation in activated macrophages , 2012, Journal of leukocyte biology.

[57]  D. Dewitt,et al.  Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stress. , 2012, Biochemical pharmacology.

[58]  Laura J. Esserman,et al.  Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.

[59]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[60]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[61]  Edward L. Huttlin,et al.  A Tissue-Specific Atlas of Mouse Protein Phosphorylation and Expression , 2010, Cell.

[62]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[63]  P. Allavena,et al.  Tumor-Associated Macrophages (TAM) as Major Players of the Cancer-Related Inflammation , 2010 .

[64]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[65]  D. Livingston,et al.  BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.

[66]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[67]  P. Allavena,et al.  Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation , 2009, Journal of leukocyte biology.

[68]  Ruth J. Muschel,et al.  A Distinct Macrophage Population Mediates Metastatic Breast Cancer Cell Extravasation, Establishment and Growth , 2009, PloS one.

[69]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[70]  J. Pollard,et al.  Macrophages define the invasive microenvironment in breast cancer , 2008, Journal of leukocyte biology.

[71]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[72]  L. Coussens,et al.  Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007, Breast Cancer Research.

[73]  J. Peterse,et al.  Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer , 2007, Proceedings of the National Academy of Sciences.

[74]  Lisa M. Coussens,et al.  Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007 .

[75]  J. Pollard,et al.  Macrophages regulate the angiogenic switch in a mouse model of breast cancer. , 2006, Cancer research.

[76]  Martin Kuiper,et al.  BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks , 2005, Bioinform..

[77]  P. Garnier,et al.  NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. , 2003, Biochemical and biophysical research communications.

[78]  F. Kishi,et al.  Functional heterogeneity of colony‐stimulating factor‐induced human monocyte‐derived macrophages , 2006, International journal of hematology.

[79]  F. Apiou,et al.  PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase* , 1999, The Journal of Biological Chemistry.

[80]  W. Wiktor-Jedrzejczak,et al.  Hematological characterization of congenital osteopetrosis in op/op mouse. Possible mechanism for abnormal macrophage differentiation , 1982, The Journal of experimental medicine.

[81]  P. Lane,et al.  Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. , 1976, The Journal of heredity.